My Bibliography

select

Shulby SA, Dolloff NG, Stearns ME, Meucci O, Fatatis A. CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res. 2004 Jul 15;64(14):4693-8. doi: 10.1158/0008-5472.CAN-03-3437. PubMed PMID: 15256432; NIHMSID:NIHMS105369.

select

Dolloff NG, Shulby SS, Nelson AV, Stearns ME, Johannes GJ, Thomas JD, Meucci O, Fatatis A. Bone-metastatic potential of human prostate cancer cells correlates with Akt/PKB activation by alpha platelet-derived growth factor receptor. Oncogene. 2005 Oct 13;24(45):6848-54. doi: 10.1038/sj.onc.1208815. PubMed PMID: 16007172; PubMed Central PMCID: PMC2712354.

select

Dolloff NG, Russell MR, Loizos N, Fatatis A. Human bone marrow activates the Akt pathway in metastatic prostate cells through transactivation of the alpha-platelet-derived growth factor receptor. Cancer Res. 2007 Jan 15;67(2):555-62. doi: 10.1158/0008-5472.CAN-06-2593. PubMed PMID: 17234763.

select

Yang W, Dolloff NG, El-Deiry WS. ERK and MDM2 prey on FOXO3a. Nat Cell Biol. 2008 Feb;10(2):125-6. doi: 10.1038/ncb0208-125. PubMed PMID: 18246039.

select

Russell MR, Jamieson WL, Dolloff NG, Fatatis A. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells. Oncogene. 2009 Jan 22;28(3):412-21. doi: 10.1038/onc.2008.390. Epub 2008 Oct 13. PubMed PMID: 18850002.

select

Matthew EM, Hart LS, Astrinidis A, Navaraj A, Dolloff NG, Dicker DT, Henske EP, El-Deiry WS. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. Cell Cycle. 2009 Dec 15;8(24):4168-75. doi: 10.4161/cc.8.24.10800. PubMed PMID: 20054236; PubMed Central PMCID: PMC2975271.

select

Talamo G, Castellani W, Dolloff NG. Prozone effect of serum IgE levels in a case of plasma cell leukemia. J Hematol Oncol. 2010 Sep 10;3:32. doi: 10.1186/1756-8722-3-32. PubMed PMID: 20828419; PubMed Central PMCID: PMC2944146.

select

Talamo G, Farooq U, Zangari M, Liao J, Dolloff NG, Loughran TP Jr, Epner E. Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma. Clin Lymphoma Myeloma Leuk. 2010 Dec;10(6):464-8. doi: 10.3816/CLML.2010.n.080. PubMed PMID: 21156463.

select

Mayes PA, Dolloff NG, Daniel CJ, Liu JJ, Hart LS, Kuribayashi K, Allen JE, Jee DI, Dorsey JF, Liu YY, Dicker DT, Brown JM, Furth EE, Klein PS, Sears RC, El-Deiry WS. Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1. Cancer Res. 2011 Aug 1;71(15):5265-75. doi: 10.1158/0008-5472.CAN-11-1383. Epub 2011 Jun 6. PubMed PMID: 21646472; PubMed Central PMCID: PMC3667402.

select

Dolloff NG, Mayes PA, Hart LS, Dicker DT, Humphreys R, El-Deiry WS. Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Sci Transl Med. 2011 Jun 8;3(86):86ra50. doi: 10.1126/scitranslmed.3001384. PubMed PMID: 21653830; PubMed Central PMCID: PMC3769950.

select

Faltas B, Zeidan A, Peters K, Das A, Joudeh J, Navaraj A, Dolloff NG, Harvey HA, Jiang Y, Allen JE, Dicker DT, El Deiry WS. Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting. J Clin Oncol. 2011 Jul 20;29(21):2946-7; author reply 2947-8. doi: 10.1200/JCO.2011.36.6179. Epub 2011 Jun 20. PubMed PMID: 21690466.

select

Hart LS, Dolloff NG, Dicker DT, Koumenis C, Christensen JG, Grimberg A, El-Deiry WS. Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle. 2011 Jul 15;10(14):2331-8. doi: 10.4161/cc.10.14.16418. Epub 2011 Jul 15. PubMed PMID: 21720213; PubMed Central PMCID: PMC3322474.

select

Gallant JN, Allen JE, Smith CD, Dicker DT, Wang W, Dolloff NG, Navaraj A, El-Deiry WS. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol Ther. 2011 Aug 1;12(3):239-51. doi: 10.4161/cbt.12.3.17034. Epub 2011 Aug 1. PubMed PMID: 21725213.

select

Wang W, Gallant JN, Katz SI, Dolloff NG, Smith CD, Abdulghani J, Allen JE, Dicker DT, Hong B, Navaraj A, El-Deiry WS. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol Ther. 2011 Aug 1;12(3):229-38. doi: 10.4161/cbt.12.3.17033. Epub 2011 Aug 1. PubMed PMID: 21725212.

select

Dolloff NG, Ma X, Dicker DT, Humphreys RC, Li LZ, El-Deiry WS. Spectral imaging-based methods for quantifying autophagy and apoptosis. Cancer Biol Ther. 2011 Aug 15;12(4):349-56. doi: 10.4161/cbt.12.4.17175. Epub 2011 Aug 15. PubMed PMID: 21757995; PubMed Central PMCID: PMC3230317.

select

Finnberg NK, Hart LS, Dolloff NG, Rodgers ZB, Dicker DT, El-Deiry WS. High-resolution imaging and antitumor effects of GFP(+) bone marrow-derived cells homing to syngeneic mouse colon tumors. Am J Pathol. 2011 Nov;179(5):2169-76. doi: 10.1016/j.ajpath.2011.07.028. Epub 2011 Oct 3. PubMed PMID: 21975022; PubMed Central PMCID: PMC3204038.

select

Talamo G, Rakszawski KL, Rybka WB, Dolloff NG, Malysz J, Berno T, Zangari M. Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high-dose melphalan in patients with multiple myeloma. Eur J Haematol. 2012 Aug;89(2):145-50. doi: 10.1111/j.1600-0609.2012.01795.x. Epub 2012 May 31. PubMed PMID: 22540279.

select

Talamo G, Dolloff NG, Sharma K, Zhu J, Malysz J. Clinical features and outcomes of plasma cell leukemia: a single-institution experience in the era of novel agents. Rare Tumors. 2012 Jun 26;4(3):e39. doi: 10.4081/rt.2012.e39. Epub 2012 Aug 14. PubMed PMID: 23087795; PubMed Central PMCID: PMC3475946.

select

Dolloff NG, Allen JE, Dicker DT, Aqui N, Vogl D, Malysz J, Talamo G, El-Deiry WS. Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9. Mol Cancer Ther. 2012 Nov;11(11):2321-30. doi: 10.1158/1535-7163.MCT-12-0578. Epub 2012 Sep 10. PubMed PMID: 22964485; PubMed Central PMCID: PMC3502072.

select

Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, Dolloff NG, Messaris E, Scata KA, Wang W, Zhou JY, Wu GS, El-Deiry WS. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013 Feb 6;5(171):171ra17. doi: 10.1126/scitranslmed.3004828. PubMed PMID: 23390247; PubMed Central PMCID: PMC4535715.

select

Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Walsh SA, Sunderland JJ, Dolloff NG, Linden MA, Zhan F, Janz S, Myers CL, Van Ness BG. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Mol Cancer Ther. 2013 Jun;12(6):1140-50. doi: 10.1158/1535-7163.MCT-12-1151. Epub 2013 Mar 27. PubMed PMID: 23536725; PubMed Central PMCID: PMC4076840.

select

Warfel NA, Dolloff NG, Dicker DT, Malysz J, El-Deiry WS. CDK1 stabilizes HIF-1α via direct phosphorylation of Ser668 to promote tumor growth. Cell Cycle. 2013 Dec 1;12(23):3689-701. doi: 10.4161/cc.26930. Epub 2013 Oct 25. PubMed PMID: 24189531; PubMed Central PMCID: PMC3903720.

select

Dolloff NG, Talamo G. Targeted therapy of multiple myeloma. Adv Exp Med Biol. 2013;779:197-221. doi: 10.1007/978-1-4614-6176-0_9. Review. PubMed PMID: 23288641.

select

Stessman HA, Lulla A, Xia T, Mitra A, Harding T, Mansoor A, Myers CL, Van Ness BG, Dolloff NG. High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma. Leukemia. 2014 Nov;28(11):2263-7. doi: 10.1038/leu.2014.214. Epub 2014 Jul 9. PubMed PMID: 25005244.

select

Dolloff NG. Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance. Adv Cancer Res. 2015;127:191-226. doi: 10.1016/bs.acr.2015.03.002. Epub 2015 Apr 11. Review. PubMed PMID: 26093901.

select

Thompson RM, Dytfeld D, Reyes L, Robinson RM, Smith B, Manevich Y, Jakubowiak A, Komarnicki M, Przybylowicz-Chalecka A, Szczepaniak T, Mitra AK, Van Ness BG, Luczak M, Dolloff NG. Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells. Oncotarget. 2017 May 30;8(22):35863-35876. doi: 10.18632/oncotarget.16262. PubMed PMID: 28415782; PubMed Central PMCID: PMC5482623.

select

Robinson RM, Reyes L, Duncan RM, Bian H, Reitz AB, Manevich Y, McClure JJ, Champion MM, Chou CJ, Sharik ME, Chesi M, Bergsagel PL, Dolloff NG. Inhibitors of the protein disulfide isomerase family for the treatment of multiple myeloma. Leukemia. 2019 Apr;33(4):1011-1022. doi: 10.1038/s41375-018-0263-1. Epub 2018 Oct 12. PubMed PMID: 30315229; PubMed Central PMCID: PMC7194280.

select

Dolloff NG. Discovery platform for inhibitors of IgH gene enhancer activity. Cancer Biol Ther. 2019;20(4):571-581. doi: 10.1080/15384047.2018.1538615. Epub 2018 Nov 27. PubMed PMID: 30481117; PubMed Central PMCID: PMC6422521.

select

Pierce MR, Robinson RM, Ibarra-Rivera TR, Pirrung MC, Dolloff NG, Bachmann AS. Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo. Leuk Res. 2020 Jan;88:106271. doi: 10.1016/j.leukres.2019.106271. Epub 2019 Nov 12. PubMed PMID: 31778912; PubMed Central PMCID: PMC6937391.

select

Robinson RM, Reyes L, Duncan RM, Bian H, Strobel ED, Hyman SL, Reitz AB, Dolloff NG. Tuning isoform selectivity and bortezomib sensitivity with a new class of alkenyl indene PDI inhibitor. Eur J Med Chem. 2020 Jan 15;186:111906. doi: 10.1016/j.ejmech.2019.111906. Epub 2019 Nov 21. PubMed PMID: 31787362; PubMed Central PMCID: PMC7212515.

select

Hurst KE, Lawrence KA, Reyes Angeles L, Ye Z, Zhang J, Townsend DM, Dolloff N, Thaxton JE. Endoplasmic Reticulum Protein Disulfide Isomerase Shapes T Cell Efficacy for Adoptive Cellular Therapy of Tumors. Cells. 2019 Nov 26;8(12). doi: 10.3390/cells8121514. PubMed PMID: 31779147; PubMed Central PMCID: PMC6953024.

select

Li X, Jiang Y, Peterson YK, Xu T, Himes RA, Luo X, Yin G, Inks ES, Dolloff N, Halene S, Chan SSL, Chou CJ. Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity. J Med Chem. 2020 May 28;63(10):5501-5525. doi: 10.1021/acs.jmedchem.0c00442. Epub 2020 May 6. PubMed PMID: 32321249; PubMed Central PMCID: PMC7684764.

select

Duncan RM, Reyes L, Moats K, Robinson RM, Murphy SA, Kaur B, Stessman HAF, Dolloff NG. ATF3 Coordinates Antitumor Synergy between Epigenetic Drugs and Protein Disulfide Isomerase Inhibitors. Cancer Res. 2020 Aug 15;80(16):3279-3291. doi: 10.1158/0008-5472.CAN-19-4046. Epub 2020 Jun 19. PubMed PMID: 32561529; PubMed Central PMCID: PMC7442646.

select

Benton TZ, Mills CM, Turner JM, Francis MJ, Solomon DJ, Burger PB, Peterson YK, Dolloff NG, Bachmann AS, Woster PM. Selective targeting of CD38 hydrolase and cyclase activity as an approach to immunostimulation. RSC Adv. 2021 Oct 8;11(53):33260-33270. doi: 10.1039/d1ra06266b. eCollection 2021 Oct 8. PubMed PMID: 35497564; PubMed Central PMCID: PMC9042253.

select

Robinson RM, Basar AP, Reyes L, Duncan RM, Li H, Dolloff NG. PDI inhibitor LTI6426 enhances panobinostat efficacy in preclinical models of multiple myeloma. Cancer Chemother Pharmacol. 2022 May;89(5):643-653. doi: 10.1007/s00280-022-04425-3. Epub 2022 Apr 5. PubMed PMID: 35381875; PubMed Central PMCID: PMC9054865.

select

Mills CM, Benton TZ, Piña I, Francis MJ, Reyes L, Dolloff NG, Peterson YK, Woster PM. Stimulation of natural killer cells with small molecule inhibitors of CD38 for the treatment of neuroblastoma. Chem Sci. 2023 Feb 22;14(8):2168-2182. doi: 10.1039/d2sc05749b. eCollection 2023 Feb 22. PubMed PMID: 36845935; PubMed Central PMCID: PMC9945084.

select

Siegel JB, Nasarre P, Hsu L, Mukherjee R, Gormley M, Richardson B, Khan I, Morningstar JE, Hilliard E, O'Bryan JP, Helke KL, Spruill L, Dolloff NG, Klauber-DeMore N. Secreted frizzled related-protein 2 is prognostic for human pancreatic cancer patient survival and is associated with fibrosis. Cancer Biomark. 2023;38(3):287-300. doi: 10.3233/CBM-220044. PubMed PMID: 37955079; PubMed Central PMCID: PMC10977449.

select

Robinson RM, Reyes L, Christopher BN, Duncan RM, Burge RA, Siegel J, Nasarre P, Wang P, O'Bryan JP, Hobbs GA, Klauber-DeMore N, Dolloff NG. A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17). Antibodies (Basel). 2024 Dec 5;13(4). doi: 10.3390/antib13040101. PubMed PMID: 39727484; PubMed Central PMCID: PMC11672854.

select

Christopher BN, Golick L, Basar A, Reyes L, Robinson RM, Angerstein AO, Krieg C, Hobbs GA, Guttridge DC, O'Bryan JP, Dolloff NG. Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in Pancreatic Cancer. Biomolecules. 2025 Apr 30;15(5). doi: 10.3390/biom15050645. PubMed PMID: 40427538; PubMed Central PMCID: PMC12108577.

select

Golick L, Robinson RM, Reyes L, St Thomas N, Klinzing K, O'Connor EC, Ferreira LMR, Dolloff NG. A superantigen-based MHC class II-targeted cancer immunotherapy for the treatment of acute myeloid leukemia. Blood Cancer J. 2025 Nov 17;15(1):198. doi: 10.1038/s41408-025-01391-w. PubMed PMID: 41249828; PubMed Central PMCID: PMC12623995.